RATIONALE: Bupropion reduces discomfort and craving associated with smoking cessation. This study determined whether a rat model of nicotine dependence could detect such nicotine abstinence-alleviating effects. OBJECTIVES: Experiments determined whether the abstinence-alleviating effects of bupropion were detectable by (1) behavioral abstinence signs precipitated by the nicotinic antagonist mecamylamine, (2) place aversion conditioned to mecamylamine-precipitated nicotine abstinence, and (3) spontaneous behavioral abstinence signs after abrupt nicotine withdrawal. METHODS: In experiments 1 and 2, nicotine-dependent rats were coinfused for 7 days with 3.15 mg/kg/day nicotine and 20 mg/kg/day bupropion or with nicotine alone. They were then challenged with 1 mg/kg mecamylamine and observed for behavioral abstinence signs (experiment 1) or place aversion conditioned to precipitated abstinence (experiment 2). In experiment 3, rats were nicotine-infused for 7 days as above. A day after termination of nicotine infusion, rats were observed for spontaneous nicotine abstinence signs before and after injection with saline or bupropion. RESULTS: In experiment 1, rats coinfused with nicotine and bupropion had significantly fewer mecamylamine-precipitated abstinence signs than rats infused with nicotine alone but similar numbers to rats infused with saline alone. In experiment 2, bupropion pretreatment significantly reduced the aversiveness of mecamylamine-precipitated nicotine abstinence. In experiment 3, a single bupropion injection dose-dependently alleviated spontaneous nicotine abstinence syndrome. CONCLUSIONS: These results suggest that these rat models of nicotine dependence and abstinence syndrome may be useful in detecting nicotine abstinence-alleviating effects of potential medications for smoking cessation. The effects of acute bupropion administration raise interesting questions regarding bupropion's mechanism of action.
RATIONALE: Bupropion reduces discomfort and craving associated with smoking cessation. This study determined whether a rat model of nicotinedependence could detect such nicotine abstinence-alleviating effects. OBJECTIVES: Experiments determined whether the abstinence-alleviating effects of bupropion were detectable by (1) behavioral abstinence signs precipitated by the nicotinic antagonist mecamylamine, (2) place aversion conditioned to mecamylamine-precipitated nicotine abstinence, and (3) spontaneous behavioral abstinence signs after abrupt nicotine withdrawal. METHODS: In experiments 1 and 2, nicotine-dependent rats were coinfused for 7 days with 3.15 mg/kg/day nicotine and 20 mg/kg/day bupropion or with nicotine alone. They were then challenged with 1 mg/kg mecamylamine and observed for behavioral abstinence signs (experiment 1) or place aversion conditioned to precipitated abstinence (experiment 2). In experiment 3, rats were nicotine-infused for 7 days as above. A day after termination of nicotine infusion, rats were observed for spontaneous nicotine abstinence signs before and after injection with saline or bupropion. RESULTS: In experiment 1, rats coinfused with nicotine and bupropion had significantly fewer mecamylamine-precipitated abstinence signs than rats infused with nicotine alone but similar numbers to rats infused with saline alone. In experiment 2, bupropion pretreatment significantly reduced the aversiveness of mecamylamine-precipitated nicotine abstinence. In experiment 3, a single bupropion injection dose-dependently alleviated spontaneous nicotineabstinence syndrome. CONCLUSIONS: These results suggest that these rat models of nicotinedependence and abstinence syndrome may be useful in detecting nicotine abstinence-alleviating effects of potential medications for smoking cessation. The effects of acute bupropion administration raise interesting questions regarding bupropion's mechanism of action.
Authors: B D Jamerson; M Nides; D E Jorenby; R Donahue; P Garrett; J A Johnston; M C Fiore; S I Rennard; S J Leischow Journal: Clin Ther Date: 2001-05 Impact factor: 3.393
Authors: Caryn Lerman; Ray Niaura; Bradley N Collins; Paul Wileyto; Janet Audrain-McGovern; Angela Pinto; Larry Hawk; Leonard H Epstein Journal: Psychol Addict Behav Date: 2004-12
Authors: M Imad Damaj; F Ivy Carroll; J Brek Eaton; Hernan A Navarro; Bruce E Blough; Sadiq Mirza; Ronald J Lukas; Billy R Martin Journal: Mol Pharmacol Date: 2004-09 Impact factor: 4.436
Authors: D H Malin; J R Lake; P Newlin-Maultsby; L K Roberts; J G Lanier; V A Carter; J S Cunningham; O B Wilson Journal: Pharmacol Biochem Behav Date: 1992-11 Impact factor: 3.533
Authors: F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young Journal: Neurosci Biobehav Rev Date: 2015-06-06 Impact factor: 8.989
Authors: M Imad Damaj; Sheri D Grabus; Hernan A Navarro; Robert E Vann; Jonathan A Warner; Lindsey S King; Jenny L Wiley; Bruce E Blough; Ronald J Lukas; F Ivy Carroll Journal: J Pharmacol Exp Ther Date: 2010-06-24 Impact factor: 4.030
Authors: Menglu Yuan; Ariana M Malagon; Dennis Yasuda; James D Belluzzi; Frances M Leslie; Nurulain T Zaveri Journal: Behav Brain Res Date: 2017-07-08 Impact factor: 3.332
Authors: Xingbao Li; Karen J Hartwell; Max Owens; Todd Lematty; Jeffrey J Borckardt; Colleen A Hanlon; Kathleen T Brady; Mark S George Journal: Biol Psychiatry Date: 2013-02-26 Impact factor: 13.382